Compelling Returns From
Funding Global Cannabinoid R&D

Financing the discovery of brand new plant-based drugs that could help
improve the lives of many people around the world.

Funding R&D companies to research the pharmacology of cannabinoids which continues to yield highly promising data and new IP across a range of therapeutic areas

Backing global-leading cannabinoid scientists which continue to explore the potential of a range of novel cannabinoid molecules in a number of distinct therapeutic areas including epilepsy, glioma, and schizophrenia

Managed by a team of proven entrepreneurs and businessmen that have a good understanding of this market

    Enter your details below to get in touch


    Funding R&D companies to research the pharmacology of cannabinoids which continues to yield highly promising data and new IP across a range of therapeutic areas

    Backing global-leading cannabinoid scientists which continue to explore the potential of a range of novel cannabinoid molecules in a number of distinct therapeutic areas including epilepsy, glioma, and schizophrenia

    Managed by a team of proven entrepreneurs and businessmen that have a good understanding of this market

    Cannabinoid
    R&D Growth

    US$16.5 billion

    Global medical cannabis market was
    worth US$16.5 billion in 2019¹

    22.8% Growth

    22.8% compound annual growth rate
    (CAGR) forecast over the 2020-25 period¹

    $58.5 billion

    Market forecast to be worth US$58.5
    billion by 2025¹

    About Cannadex

    Financing the discovery of brand new plant-based
    drugs that could help improve the lives of many
    people around the world.

    In-depth market research to identify potential investee companies with compelling R&D in medical cannabis

    Extensive face to face meetings with potential investee companies

    Due diligence and painstaking analysis of technology and business model

    Advance funds as direct investment or loans against achieving pre-agreed milestones

    Work with management teams to create value

    Appointment of key advisers and able to nominate a Non-Executive Director to the board

    Exits will be sought by way of share buy-back, listing on a recognised stock exchange, acquisition by an industrial buyer, merger with another organisation etc.

    Rapidly growing market

    Quickly being legalised in growing number of countries: Argentina, Brazil, Canada,
    Chile, Colombia, Czech, Germany, Italy, Mexico, Spain, UK, USA and Uruguay.

    US$16.5 billion

    Global medical cannabis market was
    worth US$16.5 billion in 2019¹

    22.8% Growth

    22.8% compound annual growth rate (CAGR) forecast over the 2020-25 period¹

    $58.5 billion

    Market forecast to be worth
    US$58.5 billion by 2025¹

    Global CBD Market Growing even faster¹

    More rapid growth is forecast for this sub-sector of the medical cannabis market¹

    US$553.7 million

    Global CBD market valued at
    US$553.7 million in 2020

    33.5% Growth

    by the end of 2026 growing at a CAGR
    of 33.5% during 2021-26²

    $4,268.3 million

    forecast to reach US$4,268.3 million
    by the end of 2026

    CBD wellness is an expanding category with CBD incorporated into edibles as well as being infused
    into cosmetics and pet products. Industry clamouring for CBD to listed as “generally recognised as
    safe” and so it is classified in the same way as vanilla flavouring and caffeine.

    The History of
    Medicinal Cannabis

    Medical cannabis is any cannabis-based medicine that relieves symptoms.
    Cannabis has been used medicinally for more than 4,500 years.

    In 2,727BC, Emperor Shen-Nung recognised its treatment properties in over 100 ailments including rheumatism and gout. Napoleon returned from Egypt in 1798 with cannabis which was investigated for pain relief and sedation. Elsewhere at that time, cannabis was being used to treat tumours, coughs and jaundice.

    In the early 20th century cannabis use fell out of favour with
    regulators and the culture of the western world.

    Medical cannabis
    becomes legalised

    Trend led by Canada which changed it laws in 2001 to legalise the medicinal use of cannabis

    Growing number of countries legalising cannabis for medical use

    UK regulations changed in November 2018 following public pressure

    Today the NHS prescribes medicinal cannabis for severe forms of epilepsy, nausea caused by chemotherapy and muscle stiffness/ spasms caused by MS

    Medical cannabis is still in its introductory phase in the healthcare industry

    Substantial growth is predicted for medical cannabis

    Compelling Returns From
    Funding Global Cannabinoid R&D

    Financing the discovery of brand new plant-based drugs that could help
    improve the lives of many people around the world.